Plain-English translation of NCT05139797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether artificial intelligence can reliably identify patients with cardiac amyloidosis—a rare disease where abnormal proteins build up in the heart—by analyzing standard heart ultrasound images. Doctors sometimes miss or misdiagnose this condition because it can look similar to other heart problems on imaging. The goal is to use AI to spot these patients earlier so they can receive targeted treatments that actually work.
Cardiac amyloidosis is a serious condition that can be treated effectively if caught early, but it's often missed or confused with other heart diseases because the visual signs can look alike to human eyes. This trial exists to test whether artificial intelligence can see patterns that doctors might miss and help identify patients who need specialist care sooner.
You likely qualify if…
You likely don't qualify if…
Your participation involves having your heart ultrasound images analyzed by the artificial intelligence algorithm. If the AI identifies a high probability of cardiac amyloidosis, you will be referred to a specialty heart clinic for further evaluation and testing by cardiologists. The study team will track whether the AI recommendation leads to an accurate diagnosis and appropriate treatment.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States